Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference Feb 5, 2016 05:06PM
Amgen (AMGN) Announces BLINCYTO Phase 3 TOWER Met Primary Endpoint in r/r B-Cell Precursor ALL Feb 5, 2016 07:51AM
Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Feb 4, 2016 04:17PM
Amgen (AMGN) Says Repatha Phase 3 GAUSS-3 Met co-Primary Endpoints Feb 4, 2016 04:01PM
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol Feb 4, 2016 04:00PM
View Older Stories

Jan 28, 2016 04:00PM Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38
Jan 25, 2016 05:21PM Amgen (AMGN) BLA for ABP 501 Accepted by FDA
Jan 25, 2016 05:20PM FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501
Jan 25, 2016 04:03PM Amgen Announces Webcast of 2015 Fourth Quarter and Full Year Financial Results
Jan 25, 2016 06:16AM Amgen (AMGN) Announces Vectibix + BSC Phase 3 Met Primary Endpoint
Jan 23, 2016 01:00PM Vectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer
Jan 22, 2016 06:18AM Amgen (AMGN) Announces Japanese Approval of Repatha as PCSK9 Inhibitor
Jan 22, 2016 01:00AM Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Jan 21, 2016 04:34PM Amgen (AMGN) Announces FDA Approval of Supplemental Kyprolis Combo NDA in r/r Multiple Myeloma
Jan 21, 2016 04:32PM FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Jan 7, 2016 04:05PM Amgen To Present At The 34th Annual J.P. Morgan Healthcare Conference
Dec 28, 2015 12:30PM Harris & Harris Group (TINY) Announces Receipt of BioVex Group-Related Milestone Payment
Dec 18, 2015 06:56AM Amgen (AMGN) Announces EC Approval of IMLYGIC for Unresectable Melanoma
Dec 18, 2015 01:00AM European Commission Approves Amgen's IMLYGIC™ (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe
Dec 15, 2015 04:00PM Amgen Announces 27 Percent Increase In 2016 First Quarter Dividend
Dec 15, 2015 09:24AM Pre-Open Stock Movers 12/15: (KTOV) (LL) (VRX) Higher; (NEOT) (KMT) (ZOES) Lower (more...)
Dec 14, 2015 04:01PM Amgen (AMGN) Will Reacquire All Prolia, XGEVA, and Vectibix Rights (GSK)
Dec 14, 2015 04:00PM Amgen Reacquires All Product Rights To Prolia® (denosumab), XGEVA® (denosumab) And Vectibix® (panitumumab) From GSK In 48 Countries
Dec 7, 2015 09:01AM Amgen (AMGN) Announces Presentation of Data from Three BLINCYTO Phase 2s at ASH 2015
Dec 7, 2015 09:00AM Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015
Dec 5, 2015 09:00AM New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma
Dec 5, 2015 09:00AM Pivotal Head-To-Head ENDEAVOR Study Results Published in The Lancet Oncology Demonstrate Superiority of Kyprolis® (carfilzomib) Combination Over Velcade® (bortezomib) Combination
Dec 5, 2015 08:45AM Amgen Submits Application In Europe To Expand Indication Of Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Dec 4, 2015 08:01AM Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma
Dec 4, 2015 02:00AM Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501
Nov 25, 2015 04:00PM Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration
Nov 24, 2015 02:00AM European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
Nov 23, 2015 08:10AM Amgen Announces Repatha® Preferred Position On CVS Health Commercial Formularies
Nov 19, 2015 04:00PM European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
Nov 16, 2015 04:00PM Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at the 2015 International Congress of the Society for Melanoma Research
Nov 9, 2015 05:30PM Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab
Nov 8, 2015 03:45PM Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015
Nov 8, 2015 03:45PM Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015
Nov 7, 2015 03:00PM Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
Nov 6, 2015 04:01PM FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide
Nov 5, 2015 04:01PM Amgen To Present At The Credit Suisse 24th Annual Healthcare Conference
Nov 5, 2015 09:15AM Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015
Nov 4, 2015 04:01PM Amgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health Professionals Annual Meeting
Nov 2, 2015 04:01PM Amgen To Highlight Cardiovascular Portfolio At American Heart Association Scientific Sessions 2015
Oct 28, 2015 04:01PM Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72
Oct 27, 2015 04:46PM FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US
Oct 27, 2015 08:00AM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
Oct 27, 2015 08:00AM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
Oct 23, 2015 04:01PM Amgen Announces Webcast of 2015 Third Quarter Financial Results
Oct 23, 2015 07:22AM Amgen Receives CHMP Positive Opinion For IMLYGIC™ (Talimogene Laherparepvec)
Oct 21, 2015 04:15PM Amgen Foundation Announces New $4 Million Commitment to Bring Hands-On Biotechnology Labs to Secondary School Students
Oct 14, 2015 04:18PM Amgen Announces 2015 Fourth Quarter Dividend
Oct 13, 2015 04:00PM Amgen And LabCentral Announce 2015 Golden Ticket Winners
Oct 13, 2015 09:29AM Pre-Open Stock Movers 10/13: (WPP) (PLX) (TWTR) Higher; (EOX) (HTWR) (FMC) Lower (more...)
Oct 12, 2015 04:30PM New Data Show Consistent Safety Profile For Up To 10 Years With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis
View Older Stories